Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.15 is in line with its 5-year average of -1.14, around the middle of its 5-year range (-1.36–-0.82).
8.49% below its 12-month average of -1.06.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.30.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 22 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.15
EARNINGS PER SHARE (EPS) AVG TTM
-1.06
EARNINGS PER SHARE (EPS) AVG 3Y
-1.18
EARNINGS PER SHARE (EPS) AVG 5Y
-1.14
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-8.49%
CURRENT VS 3Y AVG
+2.13%
CURRENT VS 5Y AVG
-0.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SOPHiA GENETICS S.A.
Market Cap
$619.15M
Earnings Per Share (EPS)
-1.15
TTM Avg
-1.06
3Y Avg
-1.18
5Y Avg
-1.14
Market Cap
$611.57M
Earnings Per Share (EPS)
-0.83
TTM Avg
-1.21
3Y Avg
-1.36
5Y Avg
-1.94
Market Cap
$630.63M
Earnings Per Share (EPS)
-0.36
TTM Avg
-0.59
3Y Avg
-0.49
5Y Avg
-0.39
Market Cap
$632.16M
Earnings Per Share (EPS)
-1.10
TTM Avg
-1.50
3Y Avg
-1.66
5Y Avg
-1.44
Market Cap
$634.30M
Earnings Per Share (EPS)
0.93
TTM Avg
-0.44
3Y Avg
-0.74
5Y Avg
-1.38
Market Cap
$638.20M
Earnings Per Share (EPS)
-1.78
TTM Avg
-1.75
3Y Avg
-1.85
5Y Avg
-1.69
Market Cap
$597.55M
Earnings Per Share (EPS)
0.77
TTM Avg
0.08
3Y Avg
-1.29
5Y Avg
-0.21
Market Cap
$596.01M
Earnings Per Share (EPS)
-0.88
TTM Avg
-0.85
3Y Avg
-1.91
5Y Avg
-1.52
Market Cap
$584.48M
Earnings Per Share (EPS)
-2.82
TTM Avg
-1.69
3Y Avg
-1.06
5Y Avg
3.72
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $619.15M | -1.15 | -1.06 | -1.18 | -1.14 |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | -0.83 | -1.21 | -1.36 | -1.94 |
| OmniAb, Inc. (OABI)vs › | $630.63M | -0.36 | -0.59 | -0.49 | -0.39 |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | -1.10 | -1.50 | -1.66 | -1.44 |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 0.93 | -0.44 | -0.74 | -1.38 |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | -1.78 | -1.75 | -1.85 | -1.69 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 0.77 | 0.08 | -1.29 | -0.21 |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | -0.88 | -0.85 | -1.91 | -1.52 |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | -2.82 | -1.69 | -1.06 | 3.72 |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | -1.68 | -1.67 | -1.05 | -1.14 |
Trailing EPS (TTM)
$-1.15
Forward EPS (Est.)
$-0.94
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.17 |
| 2024-12-31 | -0.95 |
| 2023-12-31 | -1.22 |
| 2022-12-31 | -1.36 |
| 2021-12-31 | -1.33 |
| 2020-12-31 | -0.82 |
| 2019-12-31 | -0.53 |
